Skip to main content
OpenTrials
Completed

NCT Number: NCT03247920

Reduction of Intravenous Antibiotics In Neonates

Randomized controlled open-label non-inferiority trial comparing complete intravenous antibiotic treatment with a short iv. course followed by oral antibiotics in neonates (0-28 days) with probable bacterial infection.

Primary outcome:

- Bacterial re-infection within 28 days after finishing of antibacterial therapy.

Secondary outcome(s):

* Pharmacokinetic profile of oral amoxicillin/clavulanic acid * Quality of life * Cost-effectiveness * Alterations in gut microbiome * Use of molecular techniques for better detection of bacterial pathogens

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–28 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Meander Medical Center, Amersfoort, Netherlands

Loading trial locations.

About this study

Neonates have a high antibiotic consumption because of their susceptibility for bacterial infections. Since the early diagnosis of bacterial infection in neonates is difficult, intravenous broad-spectrum antimicrobial therapy is usually started promptly after subtle symptoms. The majority of neonates become asymptomatic shortly after initiation; when infection is probable or proven by elevated inflammatory markers and/or a positive blood culture, intravenous antibiotics are administered for at least 7 days.

However, for neonates blood culture has a limited sensitivity. Therefore, the majority of neonates with probable infection are treated for a prolonged time with intravenous broad-spectrum antimicrobial therapy. In older children, intravenous antibiotics are often changed to oral antibiotics after cessation of symptoms and decreasing inflammatory parameters. This is not yet widely practised in neonates because of uncertainties in pharmacokinetics. Two explorative small studies from France and Italy into neonatal antibiotic switch therapy suggest that follow-up treatment with an oral antibiotic is promising; but the non-inferiority and safety was not yet properly addressed. Neonatal switch therapy, if proven to be safe and efficacious, would have a major impact on neonatal well-being, mother-to-child bonding and moreover costs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Neonates (≥ 35+0 weeks, 0-28 days old, ≥ 2 kg)
  • Probable bacterial infection defined as clinical symptoms and/or maternal risk factors and elevated inflammatory markers for which empiric broad-spectrum antibiotic treatment was initiated and needs to be continued for > 48 hours
  • Clinically well
  • Toleration of oral feeding without overt vomiting
  • Signed informed consent

Exclusion criteria

  • Proven bloodstream infection
  • Absence of blood culture
  • Severe localized infection (meningitis, osteomyelitis, necrotizing enterocolitis)
  • Severe clinical sepsis (compromised circulation, need for mechanical ventilation)
  • Continuous need for a central venous line
  • Severe hyperbilirubinemia exceeding the exchange level
  • Parents inability to administer medication
  • Major congenital or syndromic anomalies

Treatment and study plan

amoxicillin clavulanate

Drug

Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1

Antibiotics

Drug

Intravenous antibiotic therapy following local protocol

Primary outcomes

  1. Bacterial re-infection within 28 days after cessation of antibiotic treatment (within 35 days after initial presentation)

    Time frame: 0-35 days

Secondary outcomes

  1. Duration of hospitalization

    Time frame: 0-35 days after birth

  2. Percentage of re-admission

    Time frame: 0-35 days after birth

  3. Total costs and cost-effectiveness

    Time frame: 0-35 days after birth

    Cost-effectiveness of intravenous to oral switch compared to a full course of antibiotics + possible extra costs due to early antibiotic switch

  4. Difference in Quality of Life between oral and intravenous antibiotic treatment

    Time frame: 0-35 days after birth

    Two questionnaires on day 7 and 21 after admission, filled in by both parents. Data will be provided in a descriptive manner as no validated QoL questionnaires exist for neonates.

  5. Time above MIC (T>MIC) of oral amoxicillin.

    Time frame: 0-7 days

    2 blood samples after administration of antibiotic suspension at different time points will be taken.

    Time above MIC (T>MIC) will be defined. Target MIC is 8 mg/liter.

  6. Time above MIC (T>MIC) of oral clavulanic acid.

    Time frame: 0-7 days

    2 blood samples after administration of antibiotic suspension at different time points will be taken.

    Time above MIC (T>MIC) will be defined. Target MIC is 8 mg/liter.

Sponsors and collaborators

Lead sponsor

Franciscus Gasthuis

Other

Collaborators

  • Erasmus Medical Center

Registry information

Official study title

Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness

Acronym: RAIN

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Aug 14, 2017
Registry last updated
Aug 24, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.